{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:58:46Z","timestamp":1711760326916},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,29]]},"DOI":"10.7759\/cureus.57156","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T07:02:13Z","timestamp":1711695733000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Pseudomonas aeruginosa Pneumonia in a Breast Cancer Patient Despite Pegfilgrastim Administration"],"prefix":"10.7759","author":[{"given":"Yuna","family":"Fukuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunehisa","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043452613","article-title":"The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta)","volume":"10","author":"Molineux G","year":"2004","unstructured":"Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004, 10:1235-44. 10.2174\/1381612043452613","journal-title":"Curr Pharm Des"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw274","article-title":"Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)","volume":"27","author":"Mavroudis D","year":"2016","unstructured":"Mavroudis D, Matikas A, Malamos N, et al.. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2016, 27:1873-8. 10.1093\/annonc\/mdw274","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith TJ","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, et al.. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015, 33:3199-212. 10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.145.9.1621","article-title":"Pseudomonas bacteremia. Retrospective analysis of 410 episodes","volume":"145","author":"Bodey GP","year":"1985","unstructured":"Bodey GP, Jadeja L, Elting L, et al.. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985, 145:1621-9. 10.1001\/archinte.145.9.1621","journal-title":"Arch Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00338-07","article-title":"Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection","volume":"10","author":"Lodise TP Jr","year":"2007","unstructured":"Lodise TP Jr, Patel N, Kwa A, et al.. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother. 2007, 10:3510-5. 10.1128\/AAC.00338-07","journal-title":"Antimicrob Agents Chemother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.760-766.2005","article-title":"Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome","volume":"49","author":"Kang CI","year":"2005","unstructured":"Kang CI, Kim SH, Park WB, et al.. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005, 49:760-6. 10.1128\/AAC.49.2.760-766.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08043-4","article-title":"Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer","volume":"31","author":"Aapro MS","year":"2023","unstructured":"Aapro MS, Chaplin S, Cornes P, et al.. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer. Support Care Cancer. 2023, 31:581. 10.1007\/s00520-023-08043-4","journal-title":"Support Care Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0002","article-title":"NCCN guidelines insights: hematopoietic growth factors, Version 1.2020","volume":"18","author":"Becker PS","year":"2020","unstructured":"Becker PS, Griffiths EA, Alwan LM, et al.. NCCN guidelines insights: hematopoietic growth factors, Version 1.2020. J Natl Compr Canc Netw. 2020, 18:12-22. 10.6004\/jnccn.2020.0002","journal-title":"J Natl Compr Canc Netw"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial","volume":"36","author":"Roch\u00e9 H","year":"2006","unstructured":"Roch\u00e9 H, Fumoleau P, Spielmann M, et al.. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol. 2006, 36:10.1200\/JCO.2006.07.3916","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2651","article-title":"Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group","volume":"16","author":"Levine MN","year":"1998","unstructured":"Levine MN, Bramwell VH, Pritchard KI, et al.. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998, 16:2651-8. 10.1200\/JCO.1998.16.8.2651","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9744-z","article-title":"Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival","volume":"110","author":"Toi M","year":"2008","unstructured":"Toi M, Nakamura S, Kuroi K, et al.. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat. 2008, 110:531-9. 10.1007\/s10549-007-9744-z","journal-title":"Breast Cancer Res Treat"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2597-1","article-title":"Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy","volume":"23","author":"Kosaka Y","year":"2015","unstructured":"Kosaka Y, Rai Y, Masuda N, et al.. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy. Support Care Cancer. 2015, 23:1137-43. 10.1007\/s00520-014-2597-1","journal-title":"Support Care Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky J","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, et al.. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000, 18:3038-51. 10.1200\/JCO.2000.18.16.3038","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.9909","article-title":"Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications","volume":"24","author":"Klastersky J","year":"2006","unstructured":"Klastersky J, Paesmans M, Georgala A, et al.. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006, 24:4129-34. 10.1200\/JCO.2005.03.9909","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.8.868","article-title":"Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome","volume":"158","author":"Carratal\u00e0 J","year":"1998","unstructured":"Carratal\u00e0 J, Ros\u00f3n B, Fern\u00e1ndez-Sevilla A, Alcaide F, Gudiol F. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med. 1998, 158:868-72. 10.1001\/archinte.158.8.868","journal-title":"Arch Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s1201-9712(99)90017-6","article-title":"Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies","volume":"3","author":"Todeschini G","year":"1998","unstructured":"Todeschini G, Franchini M, Tecchio C, et al.. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Int J Infect Dis. 1998, 3:99-104. 10.1016\/s1201-9712(99)90017-6","journal-title":"Int J Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.255-258.2002","article-title":"Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7)","volume":"46","author":"Gibb AP","year":"2002","unstructured":"Gibb AP, Tribuddharat C, Moore RA, et al.. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7). Antimicrob Agents Chemother. 2002, 46:255-8. 10.1128\/AAC.46.1.255-258.2002","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.8245","article-title":"The first case of Pseudomonas aeruginosa bacteremic pneumonia in a cancer patient receiving pegfilgrastim","volume":"56","author":"Morita F","year":"2017","unstructured":"Morita F, Hirai Y, Suzuki K, et al.. The first case of Pseudomonas aeruginosa bacteremic pneumonia in a cancer patient receiving pegfilgrastim. Intern Med. 2017, 56:2039-42. 10.2169\/internalmedicine.56.8245","journal-title":"Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/237049-severe-pseudomonas-aeruginosa-pneumonia-in-a-breast-cancer-patient-despite-pegfilgrastim-administration","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T07:02:15Z","timestamp":1711695735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/237049-severe-pseudomonas-aeruginosa-pneumonia-in-a-breast-cancer-patient-despite-pegfilgrastim-administration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.57156","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}